Prevención Deficiency Notices and Response Timelines in Mexico

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

A deficiency notice (Prevención) is not a rejection. It is an administrative notice through which COFEPRIS identifies the points of the dossier that require clarification, supplementation or correction. Under the low-risk channel of Annex I of the 2025 agreement, corrections are divided into administrative ones with 10 days and technical ones with 15 days, and the applicant must complete the correction within 10 days. Failing to respond within the deadline causes the application to be deemed abandoned or not accepted, which means the calendar cost of a missed notice is measured in restarts, not in delays. Because the response windows are short and the consequences of missing them are severe, the deficiency notice is the stage of the Mexican filing process where preparation pays off most visibly: the categories of deficiencies are predictable, the response format can be templated in advance, and the speed of the answer depends directly on the holder’s operating capability on the DIGIPRiS platform. A team that treats the notice as routine correspondence will answer slowly; a team that treats it as a countdown will answer within the deadline almost every time, and the difference between the two postures shows up directly in approval dates.

2. Legal basis

The correction timelines of the low-risk channel come from the 2025 agreement, the form and document requirements come from the implementing regulation, and the decision period of the abbreviated pathway comes from the guidelines. The table below lists each instrument with its date or articles and the operational point it establishes.

InstrumentDate / articlesKey point
2025 low-risk agreementDOF 2025-07-15Annex I low-risk devices: decision period 20 business days; corrections, administrative 10 days, technical 15 days; applicant correction period 10 days
Reglamento de Insumos para la Salud (RIS), amendment decree DOF 2026-04-24Article 153Applications must use the official forms and attach the documents listed in the regulation
Abbreviated pathway guidelinesDOF 2025-07-18Decision period for devices 30 business days

3. Expert insights

Insight 1: a deficiency notice and a rejection are different things. Receiving a deficiency notice means the file has entered review and its gaps have been identified specifically, which is a signal of progress. Withdrawing the application in the belief that the notice is a refusal sacrifices both the official fees already paid and the queue position already earned. The correct reading of the notice is: the file is alive, the authority has told you exactly what is missing, and the task now is to answer precisely, item by item, within the days allowed.

Insight 2: administrative and technical corrections carry different periods. Administrative corrections, covering missing documents, the validity of authorization documents and payment receipts, carry 10 days; technical corrections, covering performance specifications, test data and label content, carry 15 days. The classification determines the internal preparation rhythm, because an administrative response is essentially a document-gathering exercise while a technical response may require new evidence or expert input. Assigning the two categories to different owners from the first day of the response window prevents the more urgent track from waiting behind the slower one.

Insight 3: the common grounds for deficiency concentrate in five areas. Missing documents, for example a missing test report; translations that are inaccurate or incomplete; insufficient technical information, for example performance specifications that are not clearly defined; labels or instructions for use that do not comply with local regulation; and validity problems in the authorization documents. All five can be resolved through a pre-submission self-check, which is the cheapest moment to fix them, before they become a clocked obligation. The same five categories make an excellent structure for the internal dossier review checklist.

Insight 4: the response should be written as a correspondence table. The official notice lists each deficiency item together with the provision on which it is based. Responding with a three-column table, showing the official requirement, the action taken, and the location of the corresponding new document or explanation, reduces the probability of a second deficiency round, because the reviewer can verify each point against the response without hunting through the dossier. The same table doubles as the internal record of what was changed and why.

Insight 5: the holder determines the speed of the response. The deficiency cycle closes inside DIGIPRiS and is operated through the holder’s account. The holder’s platform capability therefore directly determines whether the correction can be completed within 10 days. Where the holder is a small entity without dedicated regulatory staff, this dependency should be identified before the application is filed, not after the first notice arrives, and a substitute operator should be arranged where the capability is uncertain.

4. Practical recommendations

  • Establish a deficiency response SOP: break down the notice on the day of receipt, assign tasks the next day, complete the draft by day 3, review internally by day 5, and file by day 8, leaving buffer within the 10 days.
  • Assign responsible persons separately for administrative and technical corrections, and contact the testing laboratory and the quality system certification body early for technical items.
  • Include the correspondence table in the response package, and point out in the cover letter the location of the new document answering each deficiency item.
  • For translation-related deficiencies, engage a certified translator (perito traductor) directly; do not substitute internal translations.
  • Where authorization documents are approaching expiry, renew them before submission to avoid an administrative correction altogether.

5. Verification checklist

  • □ Administrative (10 days) and technical (15 days) corrections have been distinguished
  • □ The deficiency response SOP has been established with buffer built in
  • □ The three-column correspondence table template is ready
  • □ Certified translator resources are in place
  • □ The validity of authorization documents has been renewed in advance
  • □ The holder’s platform response capability has been confirmed

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Mexican market. Our team manages COFEPRIS registrations and equivalence (equivalencia) reviews, coordinates third-party authorised centre routes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail